January 6, 2020 / 1:15 PM / 19 days ago

BRIEF-Ironwood, Allergan Announce Settlement Resolving Linzess (Linaclotide) Patent Litigation

Jan 6 (Reuters) - Ironwood Pharmaceuticals:

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

* CO, ALLERGAN REACH DEAL WITH SANDOZ RESOLVING LINZESS (LINACLOTIDE) PATENT LITIGATION

* CO, ALLERGAN TO GRANT SANDOZ LICENSE TO MARKET 145 MCG & 290 MCG GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 5, 2030

* HATCH-WAXMAN LITIGATION BETWEEN COS & SANDOZ REGARDING LINZESS PATENTS PENDING IN US DISTRICT COURT FOR DISTRICT OF DELAWARE TO BE DISMISSED

* IRONWOOD PHARMACEUTICALS- COMPANIES WILL SUBMIT SETTLEMENT AGREEMENT TO U.S. FEDERAL TRADE COMMISSION AND U.S. DEPARTMENT OF JUSTICE FOR REVIEW

* PATENT INFRINGEMENT LITIGATION BROUGHT BY COS AGAINST TEVA PHARMACEUTICALS USA REMAIN PENDING

* TRIAL THAT WAS SCHEDULED TO BEGIN ON JAN 7 HAS BEEN POSTPONED TO ENABLE PARTIES TO CONTINUE SETTLEMENT NEGOTIATIONS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below